HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

COVID And Beyond: China Urged To Address Chronic Disease, Improve Access

Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.

China Business Strategies

Pandemic Is Enabling Faster Business Transformation, Says Novartis Digital Leader

Novartis has accelerated its digital ambitions during the worldwide lockdown period, working with partners such as Doximity on engaging doctors and Science 37 on virtual trial tech.

Commercial Companies

Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS

Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year. 

Clinical Trials Research & Development

Bristol Launches Zeposia For MS, Sees Advantages In The COVID-19 Environment

After delaying the launch of the MS treatment due to the pandemic, Bristol now says the market is ready for a new launch. Immunology US business unit head Tina Deignan talked to Scrip about it.

Launches Coronavirus COVID-19
See All

Company Information

UsernamePublicRestriction

Register